The Global Technetium-99m Market was valued at approximately USD 306.50 Million in 2023 and is projected to reach USD 419.91 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.6% during the forecast period. This growth is propelled by the rising global burden of chronic diseases like cancer and cardiovascular conditions, increasing demand for non-invasive diagnostic imaging, and significant investments in nuclear medicine infrastructure and radioisotope supply chain security.

As the cornerstone of diagnostic nuclear medicine, Technetium-99m is used in tens of millions of medical procedures worldwide each year. The stability of its supply is critical for global healthcare. In this blog, we profile the Top 10 Companies in the Technetium-99m Industry—a mix of reactor operators, radiopharmaceutical giants, and specialized producers who are ensuring reliable access to this vital medical isotope and advancing next-generation diagnostic solutions.

Download FREE Sample Report:
Technetium-99m Market – View in Detailed Research Report

---

🔟 10. Shine Medical Technologies, Inc.

Headquarters: Madison, Wisconsin, USA
Key Offering: Molybdenum-99 (Mo-99) for Technetium-99m generator production

Shine Medical Technologies is a pioneering company developing a non-fission, accelerator-based method for producing Mo-99, the parent isotope of Tc-99m. Its innovative technology aims to create a more secure, reliable, and environmentally friendly North American supply chain, reducing dependency on aging nuclear research reactors.

Innovation & Supply Initiatives:

• Building a large-scale Mo-99 production facility in the U.S.

• Partnerships with major healthcare distributors to ensure rapid delivery to hospitals.

• Focused on eliminating highly enriched uranium (HEU) from the medical isotope supply chain.

---

9️⃣ 9. NorthStar Medical Radioisotopes, LLC

Headquarters: Beloit, Wisconsin, USA
Key Offering: RadioGenix® System (Non-uranium based Mo-99), Tc-99m generators.

NorthStar is a leader in securing the U.S. supply of Mo-99 and Tc-99m without using highly enriched uranium. Its RadioGenix® System is FDA-approved and represents a major step forward in domestic, stable isotope production, utilizing electron accelerator technology to irradiate Mo-100 targets.

Innovation & Supply Initiatives:

• First and only FDA-approved Tc-99m generator using non-uranium Mo-99 in the U.S.

• Strategic alliances with BWXT and other partners for large-scale production.

• Committed to providing a consistent, weekly supply of Mo-99 to pharmacies and hospitals.

---

8️⃣ 8. JSC Isotope (a Rosatom State Corporation enterprise)

Headquarters: Moscow, Russia
Key Offering: Mo-99, Tc-99m generators, a wide range of medical radioisotopes.

JSC Isotope manages the production and distribution of radioisotopes for Rosatom, one of the world’s largest nuclear corporations. It operates a significant portion of the global Mo-99 production capacity through its network of research reactors and processing facilities in Russia.

Innovation & Supply Initiatives:

• Major global supplier, contributing to over 20% of the world’s Mo-99 needs.

• Investing in modernization of reactor and processing facilities to increase output and reliability.

• Expanding its international footprint through supply agreements across Europe, Asia, and Latin America.

Download FREE Sample Report:
Technetium-99m Market – View in Detailed Research Report

---

7️⃣ 7. ANSTO (Australian Nuclear Science and Technology Organisation)

Headquarters: Lucas Heights, New South Wales, Australia
Key Offering: Mo-99, ANSTOtec® Technetium-99m Generators.

ANSTO is Australia’s national nuclear organization and a critical global supplier of Mo-99, produced in the OPAL multipurpose reactor. It manufactures and distributes Tc-99m generators under the ANSTOtec® brand, serving the Asia-Pacific region and beyond with a focus on reliable, LEU-based production.

Innovation & Supply Initiatives:

• Operates one of the newest and most modern Mo-99 production facilities globally.

• Produces enough Mo-99 to supply up to 25% of global demand outside of North America.

• Active in R&D for next-generation radiopharmaceuticals and targeted alpha therapies.

---

6️⃣ 6. IBA RadioPharma Solutions

Headquarters: Louvain-la-Neuve, Belgium
Key Offering: Cyclotron-based isotope production systems, radiopharmaceutical manufacturing services.

While known for its proton therapy systems, IBA is a significant player in the radioisotope ecosystem. Through its RadioPharma Solutions division, IBA provides cyclotron technology and services that support the production of isotopes, including those for SPECT imaging, and is involved in research for novel production routes for Tc-99m equivalents.

Innovation & Supply Initiatives:

• Develops and markets cyclotrons used for research and production of medical isotopes.

• Offers contract manufacturing and development services for radiopharmaceutical companies.

• Engaged in partnerships to explore direct cyclotron production of Tc-99m.

---

5️⃣ 5. Sumitomo Heavy Industries, Ltd.

Headquarters: Tokyo, Japan
Key Offering: Cyclotrons, Proton Therapy Systems, Radioisotope Production Systems.

Sumitomo Heavy Industries (SHI) is a leading manufacturer of particle accelerators, including cyclotrons essential for producing a variety of medical radioisotopes. Its technology is foundational for many regional radioisotope production centers worldwide, supporting the radiopharmaceutical supply chain that includes Tc-99m precursor materials.

Innovation & Supply Initiatives:

• A global leader in supplying compact cyclotrons to hospitals and production facilities.

• Cyclotrons are used in research for producing Mo-99/Tc-99m via alternative (non-fission) methods.

• Contributes to decentralizing and securing isotope supplies through accessible accelerator technology.

---

4️⃣ 4. Advanced Cyclotron Systems Inc. (ACSI)

Headquarters: Richmond, British Columbia, Canada
Key Offering: TR Series Cyclotrons, TRIUMF-based isotope production expertise.

ACSI designs and manufactures high-energy cyclotrons used globally for the production of medical radioisotopes. Its technology is crucial for both established isotopes and research into novel theranostic agents. The company plays an indirect but vital role in the Tc-99m ecosystem by enabling research into future production methods and supporting the broader nuclear medicine infrastructure.

Innovation & Supply Initiatives:

• Cyclotrons support biomedical research that underpins new diagnostic imaging techniques.

• Collaboration with research institutions like TRIUMF on isotope production projects.

• Provides the hardware backbone for regional radioisotope production networks.

---

3️⃣ 3. Siemens Healthineers

Headquarters: Erlangen, Germany
Key Offering: SPECT & SPECT/CT Imaging Systems, Symbia® product line, Radiopharmacy equipment.

Siemens Healthineers is a titan in medical imaging, and its technology is a primary endpoint for Technetium-99m. The company’s SPECT and SPECT/CT scanners are used globally to perform the diagnostic procedures enabled by Tc-99m-based radiopharmaceuticals. Furthermore, it provides solutions for radiopharmacies that prepare the patient doses.

Innovation & Supply Initiatives:

• Develops advanced imaging systems that maximize the diagnostic yield from Tc-99m scans.

• Offers comprehensive solutions from radiopharmacy workflow to image analysis.

• Invests in digital health and AI to improve the efficiency and accuracy of nuclear medicine diagnostics.

Read Full Report:
Technetium-99m Market – View in Detailed Research Report

---

2️⃣ 2. GE HealthCare

Headquarters: Chicago, Illinois, USA
Key Offering: SPECT/CT scanners (NM/CT series), Radiopharmacy synthesis modules, Contrast Media & Pharmaceuticals.

GE HealthCare is a dominant force in the nuclear medicine landscape. Its imaging systems are instrumental in utilizing Tc-99m for patient diagnostics. While not a primary producer of the raw isotope, GE is integral to the ecosystem, providing the technology for dose calibration, imaging, and, through its pharmaceutical arm, potentially partnering on agent development.

Innovation & Supply Initiatives:

• Manufactures industry-leading nuclear medicine cameras used in millions of Tc-99m procedures annually.

• Develops digital platforms for dose management and imaging protocol optimization in nuclear medicine.

• Strategic focus on theranostics, bridging diagnostic imaging (often involving isotopes like Tc-99m) with targeted radiotherapy.

---

1️⃣ 1. Curium Pharma

Headquarters: St. Louis, Missouri, USA
Key Offering: Technetium Tc-99m Generators, CardioGen-82®, Technetium Tc-99m Exametazime, and other SPECT imaging agents.

Curium is the world’s leading nuclear medicine company, born from the merger of Mallinckrodt Nuclear Medicine and IBA Molecular. It holds a commanding position in the global supply chain for Technetium-99m, manufacturing and distributing the vital generators and cold kits that hospitals and pharmacies use to prepare patient-specific diagnostic doses daily.

Innovation & Supply Initiatives:

• The largest global supplier of Mo-99/Tc-99m generators and associated diagnostic kits.

• Manages a complex, global logistics network to ensure timely delivery of short-half-life products.

• Invests heavily in securing a diversified and resilient supply of Mo-99 through partnerships with multiple producers worldwide, including ANSTO and IRE.

Get Full Report Here:
Technetium-99m Market – View in Detailed Research Report

---

🏥 Outlook: A Future of Secure Supply and Advanced Diagnostics

The Technetium-99m market is undergoing a fundamental transformation. While traditional reactor-based production remains the backbone, the industry is aggressively investing in alternative production technologies, supply chain diversification, and next-generation diagnostic platforms to ensure resilience and drive growth.

📈 Key Trends Shaping the Market:

• Supply Chain Diversification: Accelerator-based (non-fission) production by companies like NorthStar and SHINE is reducing reliance on a handful of aging nuclear reactors, enhancing global supply security.

• Regional Self-Sufficiency: Governments in North America, Europe, and Asia-Pacific are funding domestic production capabilities to ensure uninterrupted access to this critical medical isotope.

• Integration with Theranostics: The rise of targeted radionuclide therapy (e.g., with Lutetium-177) is strengthening the overall nuclear medicine sector, with SPECT imaging using Tc-99m often playing a complementary diagnostic role.

• Technological Advancements: Development of new Tc-99m-based biomarkers for neurology, oncology, and cardiology is expanding the clinical application base, driving sustained demand.

Get Full Report Here:
Technetium-99m Market – View in Detailed Research Report

The companies listed above are not only supplying a lifeline for modern diagnostics—they are engineering a more robust and innovative future for global nuclear medicine.